Underwhelming data detract from perampanel's innovative mechanism in epilepsy
This article was originally published in Scrip
Executive Summary
Eisai signalled that it will remain a player in the epilepsy field following the unveiling of positive data from the latest Phase III clinical trial of its novel anti-epileptic drug perampanel at the 29th International Epilepsy Congress in Rome. Dr Jacqueline French, Director of the Clinical Trials Consortium at New York University’s Epilepsy Center, presented new clinical trial data from perampanel's third and final Phase III clinical trial (Study 305) of its EXPLORE (Examining Perampanel Observations from Research Experience) clinical trial programme.